If you have lost a Phase II award and wondered why a technically excellent project fell short, the answer is almost always the same: a thin commercialization plan. Review panel debriefs identify a weak commercialization narrative as a top-three rejection reason, with roughly 30% of unsuccessful Phase II submissions losing on this section alone. The section is typically 20–30% of the score, yet most applicants underweight it.
This guide covers what a strong Phase II commercialization plan looks like, what NIH, NSF, and DoD reviewers actually want, and the rejection patterns to avoid. Run the checklist before you submit, and consider a mock-review pass before your draft leaves your desk.
See also our complete SBIR/STTR grants guide for the broader Phase II landscape.
Why Phase II Commercialization Plans Get Rejected
Phase II commercialization plans get rejected not because the technology has no commercial potential, but because the applicant has not made the case. The plan reads like a hope, not a path. Four patterns show up over and over.
Vague market or customer. Saying the technology "has broad commercial applications in healthcare, defense, and energy" reads as if you have not thought about which market you enter first. Reviewers want a defined beachhead market, a named first customer, and a specific use case.
No letters of interest or memoranda of understanding. A commercialization narrative that names no customer or partner in writing is just an opinion. At Phase II, you should have at least two or three LOIs from prospective buyers, integrators, or test sites that reference your specific product.
Misalignment with agency priorities. A commercialization story framed for a market outside the agency's mission is scored down, even if true. DoD wants transition potential and dual-use. NIH wants public-health outcomes. NSF wants broader societal impact. Tell the story for the agency funding you.
Missing business model. Reviewers want to know how you will make money — pricing, unit economics, distribution, sales motion, and post-SBIR funding plan. Without it, you are pitching a research project, not a commercializing company.
What a Strong Commercialization Plan Includes
Exact section requirements vary by agency, but strong plans consistently include eight elements. Use this as a working outline; you do not need all eight subsections if your topic does not call for regulatory or IP depth, but you should be able to defend each when asked.
1. Market sizing with cited sources
Provide a top-down (TAM/SAM/SOM) and bottom-up estimate. Cite every number — IDC, Gartner, NIH prevalence data, agency program budgets. Reviewers discount uncited projections and reward numbers that match public data.
2. Named prospective customers
Name the actual prospective buyers you have talked to. "Hospitals" is not a customer; "the cardiology group at [named system]" is. The plan should reference real conversations and a credible follow-on pipeline.
3. Letters of interest or MOUs
Include two to four LOIs or MOUs from prospective customers, integrators, channel partners, or agency program offices. Each should reference your specific product and the buyer's intended use. Generic "we are interested in your technology" letters score low.
4. Intellectual property position
Describe issued patents, pending applications, and freedom-to-operate status. If you have licensed IP from a university, name the license. Reviewers need confidence that the company can commercialize without third-party blockers.
5. Regulatory pathway
If you are in medical devices, diagnostics, or therapeutics, outline the FDA pathway — 510(k), De Novo, PMA, or Breakthrough designation. Include milestones, expected cost, and contingency for delay. NIH reviewers care about this more than DoD.
6. Business model with unit economics
Show how you charge customers — license, subscription, hardware, services — and the unit economics that make it work: cost to deliver, gross margin, CAC, LTV. Reviewers need to see the math close without a full financial model.
7. Post-SBIR / Phase III funding plan
Describe how you will fund commercialization after Phase II ends — venture capital, non-dilutive government contracts (follow-on DoD procurements, NIH Phase IIB, BARDA, ARPA-H), commercial revenue, or strategic partnerships. Include committed or in-discussion amounts.
8. Team transition plan
Identify the people who take the technology from R&D to commercial. A common failure mode is concentrating all technical expertise in one founder with no commercial leadership. Include a CTO, a CEO or commercial lead, regulatory consultants, and clinical or domain advisors named in the plan.
Agency-Specific Nuance
The same commercialization story can score high at one agency and low at another. Reviewer priorities differ, and the section you emphasize should match the mission of the funding agency.
NIH
NIH reviewers score commercialization through a healthcare lens. Emphasize rigor and reproducibility, alignment to public-health benefit, and downstream clinical or commercial translation. The plan should connect the proposed work to unmet medical need, regulatory pathway, and reimbursement strategy. NIH has tightened commercialization scoring across its institutes in recent years — vague "we expect this to improve patient outcomes" language no longer moves the needle. Cite specific institute priorities (NCI, NIAID, NHLBI, NINDS) and define patient populations, partners, and downstream funding sources.
NSF
NSF evaluates broader impacts alongside intellectual merit. The broader-impacts review criterion is built into SBIR/STTR evaluation, and a strong commercialization plan maps directly to it. Emphasize societal benefit, broadening participation, workforce development, and underrepresented-group engagement. NSF rewards projects that explicitly bridge research and commercialization — publishing plans, open-source contributions, or university spin-out pathways. Reference PAPPG broader-impacts criteria when framing the plan.
DoD
DoD commercialization is about transition potential. Army, Navy, Air Force, DARPA, and OSD reviewers score the section on whether the technology moves from Phase II into a follow-on DoD procurement contract, a prime integration, or a PEO sustainment program. Name the specific program office, the non-SBIR funding source (OUSD R&E procurement, service transition programs, SBIR Phase III), and the dual-use applications. An engaged program office or prime integrator carries significant weight.
Pre-Submission Checklist
Run through this checklist before you submit. Each row maps to something a panel reviewer will look for, and missing items are the difference between funding and rejection.
| Item | Why it matters |
|---|---|
| Top-down TAM/SAM/SOM with cited sources | Reviewers discount uncited projections. Citing IDC, Gartner, or NIH data makes numbers credible. |
| Named prospective customers in writing | Verbal interest is not evidence. Two to four LOIs or MOUs are the standard. |
| Issued patents or licensed IP | Without IP, you cannot commercialize. FTO analysis is the second-order requirement. |
| Regulatory pathway for medical products | 510(k) / De Novo / PMA / Breakthrough — name the path and timing. |
| Business model with unit economics | Subscription, license, hardware, services — show gross margin and customer economics. |
| Post-SBIR / Phase III funding plan | VC, non-dilutive government contracts, or revenue — name commitments and pipeline. |
| Commercial team named | CTO + business lead + regulatory advisors. No solo-founder plans. |
| Agency-mission alignment | NIH: public-health outcomes. NSF: broader impacts. DoD: transition potential. |
| Quantified Phase III milestones | "Capture $X in follow-on contracts by year 3" beats "achieve commercial success". |
| Risk section for the plan itself | What if the regulatory timeline slips? What if the market shifts? Show you planned for it. |
Common Rejection Patterns
Most failed plans fall into a handful of patterns. If your draft reads like any of these, rework before submitting.
- All upside, no risk. Plans that describe a flawless path to market without acknowledging what could go wrong read as naive. Reviewers want to see considered risk and mitigation.
- TAM without SOM. Citing a $50B total addressable market without a credible serviceable obtainable market (the share you can actually reach in 3 years) is a red flag.
- Industry letters that do not reference your product. A letter saying "we are interested in novel sensor technology" is not an LOI for your product. Letters must reference what you are actually building.
- No regulatory section for medical devices. If your device requires FDA clearance and your plan has no regulatory subsection, you have already lost NIH and ARPA-H reviewers.
- Generic business model. "Sell to government and commercial customers" is not a business model. Name the channel, the price, and the sales motion.
- No transition from R&D leadership to commercial leadership. If your entire team is technical, reviewers worry about whether you can execute the commercial side.
Get a 1-page critique of your commercialization plan
Our mock-review service reads your Phase II proposal the way a panel would — commercialization plan, technical approach, budget, PI fit — and sends back a written critique within one business day.
Submit for mock review →Frequently Asked Questions
A strong commercialization plan is the single biggest differentiator between funded and unfunded SBIR Phase II proposals. Spend as much time on it as you do on the technical approach. Recruit a reviewer outside your field to read it cold. If you can run it through our mock-review service before submission, do — a one-day expert critique routinely catches the market and customer gaps that cost six months of work in review panel scoring.